Lund University Hospital
Clinical trials sponsored by Lund University Hospital, explained in plain language.
-
Triple-Drug chemo blitz aims to boost stomach cancer survival
Disease control OngoingThis phase 2 trial tests whether adding a third chemotherapy drug (irinotecan) to the standard two-drug regimen (FOLFOX) improves outcomes for patients with resectable stomach or gastroesophageal junction cancer. 60 participants receive the three-drug combo before and after surge…
Phase: PHASE2 • Sponsor: Lund University Hospital • Aim: Disease control
Last updated Jun 26, 2026 16:23 UTC
-
Could adding capecitabine boost chemo success in Triple-Negative breast cancer?
Disease control OngoingThis phase 3 trial tests whether adding the drug capecitabine to standard chemotherapy improves outcomes for people with early triple-negative breast cancer. The study involves 325 participants and aims to see if the combination leads to a higher rate of complete tumor disappeara…
Phase: PHASE3 • Sponsor: Lund University Hospital • Aim: Disease control
Last updated Jun 26, 2026 15:52 UTC